Skip to Content
Merck
CN
  • Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture.

Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture.

FEBS open bio (2014-10-29)
Majambu Mbikay, Francine Sirois, Sonia Simoes, Janice Mayne, Michel Chrétien
ABSTRACT

Low-density lipoprotein receptor (LDLR) mediates hepatic clearance of plasma cholesterol; proprotein convertase subtilisin/kexin 9 (PCSK9) opposes this clearance by promoting LDLR degradation. The plant flavonoid quercetin-3-β-d-glucoside (Q3G) has been shown to reduce hypercholesterolemia in experimental animals. Here, we examined how it affects LDLR and PCSK9 expression as well as LDL uptake by human Huh7 hepatocytes. At low micromolar concentrations, Q3G increased LDLR expression, reduced PCSK9 secretion, and stimulated LDL uptake. It also diminished intracellular sortilin, a sorting receptor known to facilitate PCSK9 secretion. Thus, as an LDLR inducer and a PCSK9 anti-secretagogue, Q3G may represent an effective anti-cholesterolemic agent.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Phenylindole, technical grade, 95%
Supelco
Simvastatin, analytical standard
Sigma-Aldrich
Simvastatin, ≥97% (HPLC), solid
Sigma-Aldrich
DAPI, for nucleic acid staining
Supelco
Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
N,O-Bis(trimethylsilyl)acetamide, synthesis grade, ≥95%
Simvastatin, European Pharmacopoeia (EP) Reference Standard
Supelco
N,O-Bis(trimethylsilyl)acetamide, derivatization grade (GC derivatization), LiChropur, ≥98.5% (GC)
USP
Simvastatin, United States Pharmacopeia (USP) Reference Standard